Want to see SE:ALZCUR full AI Analyst Report?

AlzeCure Pharma AB (ALZCUR) Price & Analysis

0 Followers

ALZCUR Stock Chart & Stats

kr2.44

kr0.16(7.05%)

At close: Mar 06 4:00 PM EST

kr2.44

kr0.16(7.05%)

Day’s Range― - ―

52-Week Rangekr1.14 - kr8.68

Previous CloseN/A

Volume72.39K

Average Volume (3M)348.78K

Market Cap

kr932.19M

Enterprise Valuekr522.18M

Total Cash (Recent Filing)kr32.97M

Total Debt (Recent Filing)kr2.29M

Price to Earnings (P/E)45.3

Beta0.30

Next Earnings

Nov 11, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.53

Shares Outstanding137,897,340

10 Day Avg. Volume149,030

30 Day Avg. Volume348,783

Financial Highlights & Ratios

PEG Ratio-1.96

Price to Book (P/B)6.11

Price to Sales (P/S)0.00

P/FCF Ratio-5.81

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.35

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low LeverageLow leverage provides more financial flexibility than a heavily indebted biotech, reducing interest and refinancing pressure. This can preserve capacity to direct capital toward clinical development, although the benefit is tempered by the company’s ongoing losses and declining equity base.

Proprietary CNS PipelineA proprietary small-molecule pipeline focused on major CNS diseases gives the company a defined platform for creating future partnering or commercialization opportunities. Progress across several candidates could support value creation through licensing, co-development, milestones, and royalties.

Losses Below Prior ExtremesAlthough the company remains unprofitable, losses are described as less extreme than in FY2021–FY2022. If this relative moderation persists while development continues, it could help contain the rate of capital consumption and extend the period available to advance pipeline programs.

Bears Say

No Operating RevenueZero revenue means the company currently lacks a commercial earnings base to fund research and development internally. Its financial outlook therefore depends on successful clinical progress, future partnering, or additional financing rather than recurring product or collaboration income.

Heavy Cash BurnSubstantial negative operating and free cash flow indicates that development spending is consuming cash faster than the business generates it. Continued burn creates ongoing funding needs and can constrain strategic flexibility if financing or partnering proceeds do not keep pace.

Shrinking Equity BaseThe sharp reduction in equity shows that accumulated losses and cash consumption are eroding the capital base. Deeply negative returns on equity reinforce that invested capital is not yet producing returns, increasing dependence on future financing or value-creating partnerships.

ALZCUR FAQ

What was AlzeCure Pharma AB’s price range in the past 12 months?

AlzeCure Pharma AB lowest stock price was kr1.14 and its highest was kr8.68 in the past 12 months.

What is AlzeCure Pharma AB’s market cap?

AlzeCure Pharma AB’s market cap is kr932.19M.

When is AlzeCure Pharma AB’s upcoming earnings report date?

AlzeCure Pharma AB’s upcoming earnings report date is Nov 11, 2026 which is in 29 days.

How were AlzeCure Pharma AB’s earnings last quarter?

AlzeCure Pharma AB released its earnings results on Aug 26, 2026. The company reported kr0.581 earnings per share for the quarter.

Is AlzeCure Pharma AB overvalued?

According to Wall Street analysts AlzeCure Pharma AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does AlzeCure Pharma AB pay dividends?

AlzeCure Pharma AB does not currently pay dividends.

What is AlzeCure Pharma AB’s EPS estimate?

AlzeCure Pharma AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does AlzeCure Pharma AB have?

AlzeCure Pharma AB has 137,897,340 shares outstanding.

What happened to AlzeCure Pharma AB’s price movement after its last earnings report?

AlzeCure Pharma AB reported an EPS of kr0.581 in its last earnings report. Following the earnings report the stock price went down -1.875%.

Which hedge fund is a major shareholder of AlzeCure Pharma AB?

Currently, no hedge funds are holding shares in SE:ALZCUR

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

AlzeCure Pharma AB

AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer’s disease, sleep disorders, depression, traumatic brain injuries, and Parkinson’s disease, which is in phase I clinical trial; ACD857, ACD679, and ACD680 that are in preclinical trial for the treatment of Alzheimer’s disease; ACD440, a TRPV1 antagonist that has completed phase I clinical trial for neuropathic pain indications; and ACD137, negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications. The company was founded in 2012 and is based in Huddinge, Sweden.